A Phase I Dose-escalation Trial of vvDD-CDSR (Double-deleted Vaccinia Virus Plus CD/ SMR) Administered by Intratumoral Injection or Intravenous Injection.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs JX 929 (Primary) ; JX 929 (Primary)
Indications Breast cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Pancreatic cancer; Squamous cell cancer
Focus Adverse reactions

26 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
03 Dec 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
06 Sep 2012 Actual initiation date changed from 1 Feb 2008 to 1 May 2008 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com